Loading...
Palvella Therapeutics, Inc.
PVLA•NASDAQ
Healthcare
Biotechnology
$38.62
$-0.01(-0.03%)
Palvella Therapeutics, Inc. (PVLA) Financial Performance & Income Statement Overview
Review Palvella Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-18.75%
↓ 18.75%
Net Income Growth
-193.27%
↓ 193.27%
Operating Cash Flow Growth
20.89%
↑ 20.89%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-59.37%
↓ 59.37%
ROIC
-18.50%
↓ 18.50%
Palvella Therapeutics, Inc. (PVLA) Income Statement & Financial Overview
Review Palvella Therapeutics, Inc.'s (PVLA) income statement with detailed quarterly and annual figures.
| Metric | Q1 2024 |
|---|---|
| Revenue | $0.00 |
| Cost of Revenue | $0.00 |
| Gross Profit | $0.00 |
| Gross Profit Ratio | $0.00 |
| R&D Expenses | $984000.00 |
| SG&A Expenses | $775000.00 |
| Operating Expenses | $1.76M |
| Total Costs & Expenses | $1.76M |
| Interest Income | $0.00 |
| Interest Expense | $805000.00 |
| Depreciation & Amortization | $0.00 |
| EBITDA | -$1.73M |
| EBITDA Ratio | |
| Operating Income | -$1.76M |
| Operating Income Ratio | |
| Other Income/Expenses (Net) | -$777000.00 |
| Income Before Tax | -$2.54M |
| Income Before Tax Ratio | |
| Income Tax Expense | $0.00 |
| Net Income | -$2.54M |
| Net Income Ratio | |
| EPS | -$0.24 |
| Diluted EPS | -$0.24 |
| Weighted Avg Shares Outstanding | $11.22M |
| Weighted Avg Shares Outstanding (Diluted) | $11.22M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan